OTC Watch

All stocks / RVPH

REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH

Reviva Pharmaceuticals Holdings (RVPH): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQBCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
REVIVA PHARMACEUTICALS HOLDINGS INC
Market tier
OTCQB
Trading status
Active
Last trade
09:35:27
Source: Stockwatch, 2026-11-17

News headlines

Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 20:13 · News Release
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
2026-09-22 08:00 · News Release
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 16:30 · News Release
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
2026-06-23 08:00 · News Release
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
2026-05-18 08:00 · News Release
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 16:35 · News Release
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications
2026-04-23 08:00 · News Release
Reviva Announces Letter to Shareholders
2026-04-15 08:00 · News Release
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
2026-03-30 06:05 · News Release
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
2026-03-23 08:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($19,864,902)
What it means

It spends more than it earns

Under strain

The company lost $19.9 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$14,438,792
Net cash used in operating activities
($24,594,643)
What it means

The cash could run out soon

Under strain

It had $14.4 million in the bank and used about $2 million a month. At that pace the money lasts about 7 months unless it borrows or sells more shares.

The report says
Total assets
$15,923,198
Total liabilities
$7,275,553
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $15.9 million. Its debts and unpaid bills add up to $7.3 million. That is about $0.46 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-10

Estimated float about 13,110,377 shares as of 2026-11-10: 13,110,377 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-12-31
5.9M
2026-03-27
12.8M
2026-03-31
12.8M
2026-05-13
13.1M
2026-06-30
13.1M
2026-08-13
13.1M
2026-09-30
13.1M
2026-11-10
13.1M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 8-KFORM 8-K
2026-11-13 10-QFORM 10-Q
2026-11-09 DEF 14AFORM DEF 14A
2026-11-09 ARSFORM ARS
2026-10-29 PRE 14AFORM PRE 14A
2026-08-13 SCHEDULE 13G/A
2026-08-12 8-KFORM 8-K
2026-08-12 10-QFORM 10-Q
2026-08-03 SCHEDULE 13G/A
2026-07-31 SCHEDULE 13G/A
2026-07-10 25-NSE
2026-05-15 SCHEDULE 13G/A

Common questions about RVPH

Does RVPH file reports with the SEC?

Yes. Reviva Pharmaceuticals Holdings files with the SEC under company number 0001742927. The most recent filing we hold is a 8-K dated 2026-11-13.

Source record

How many RVPH shares are outstanding?

13,110,377 shares as of 2026-11-10, as reported to the SEC.

Source record

Has RVPH filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Reviva Pharmaceuticals Holdings?

Officers named in its insider filings: Laxminarayan Bhat (President and CEO) and Narayan Prabhu (Chief Financial Officer).

Source record

Is Reviva Pharmaceuticals Holdings making money?

The company lost $19.9 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record